Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on LATAM Daily Brief.
Press releases published on June 2, 2025
Consolidated Water Increases Dividend and Declares Third Quarter Cash Dividend of $0.14 per Share
GlobeNewswire
·
June 2, 2025
GEORGE TOWN, Cayman Islands, June 02, 2025 (GLOBE NEWSWIRE) -- Consolidated Water Co. Ltd. (NASDAQ Global Select Market: CWCO), a leading designer, builder and operator of advanced water supply and treatment plants, has increased its quarterly cash …
Rakovina Therapeutics Announces 2025 Q1 Financial Results and Provides Corporate Update
GlobeNewswire
·
June 2, 2025
VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO) (“Rakovina” or the “Company”), a biopharmaceutical company advancing novel DNA-damage response (DDR) cancer therapies powered by artificial …
IAEA Approves SAIHEAT as Official SMR Vendor
GlobeNewswire
·
June 2, 2025
SINGAPORE, June 02, 2025 (GLOBE NEWSWIRE) -- SAIHEAT Limited (“SAIHEAT” or the “Company”) (NASDAQ: SAIH, SAITW), is pleased to announce that the International Atomic Energy Agency (“IAEA”) has officially approved SAIHEAT as a vendor of small modular …
Robex Reports Operational and Financial Results for Q1 2025
GlobeNewswire
·
June 2, 2025
QUÉBEC CITY, June 02, 2025 (GLOBE NEWSWIRE) -- Robex Resources Inc. ("Robex" or the "Company") (TSXV: RBX/ASX: RXR) Matthew Wilcox, Managing Director, commented: "The company has had a strong start to 2025, construction continues to advance at Kiniero, and …
Fancamp Announces Appointment of CIO
GlobeNewswire
·
June 2, 2025
VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Fancamp Exploration Ltd. (“Fancamp” or the “Corporation”) (TSX Venture Exchange: FNC) is pleased to announce the appointment of Mr. Kit Spring to the position of Chief Investment Officer (“CIO …
Mersana Therapeutics Reports Additional Positive Interim Phase 1 Clinical Data for Emi-Le in Oral Presentation at 2025 ASCO Annual Meeting
GlobeNewswire
·
June 2, 2025
31% confirmed ORR (8 responses in 26 evaluable patients) across B7-H4 high tumors at intermediate doses 44% confirmed ORR (7 responses in 16 evaluable patients) in the subset of patients with ≤4 prior lines of therapy CAMBRIDGE, Mass., June 02, 2025 (GLOBE …
Enterome to present positive Phase 2 indolent non-Hodgkin lymphoma data for its OncoMimics™ EO2463 at ICML
GlobeNewswire
·
June 2, 2025
Presentation at the International Conference on Malignant Lymphoma (ICML) in Lugano on June 21 SIDNEY is an ongoing Phase 2 trial of EO2463 in 48 indolent Non-Hodgkin Lymphoma (iNHL) patients Enterome has held a positive Type-C meeting with FDA for …
SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting
GlobeNewswire
·
June 2, 2025
- ASCO Presentation Supports SLS009 as a Potential Targeted Therapy for ASXL1 Mutated Colorectal Cancer – - 22,500 New Cases of Colorectal Cancer with High Microsatellite Instability per Year in the US: 55% ASXL1m Frequency – NEW YORK, June 02, 2025 (GLOBE …
Aventis Energy Announces Appointment of Michael Mulberry to the Board of Directors
GlobeNewswire
·
June 2, 2025
VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Aventis Energy Inc. (“Aventis” or the “Company”) (CSE: AVE | FRA: C0O0 | OTC: VBAMF), is pleased to announce that Mr. Michael Mulberry has been appointed to the board of directors of the …
PDS Biotech Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune® HPV to Treat Head and Neck Cancers at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire
·
June 2, 2025
Median overall survival data in first-line recurrent/metastatic (1L r/m) HNSCC remains durable at 30.0 months with additional follow-up of ~4.5 months beyond the initial abstract HPV16-positive is the most rapidly increasing HNSCC in the US VERSATILE-003 …
Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting
GlobeNewswire
·
June 2, 2025
Dosing cohort 3 of Phase 1 trial of CTIM-76, a Claudin 6 x CD3 T cell engager Expect to share initial data in the first half of 2026 PHILADELPHIA, June 02, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a …
BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025
GlobeNewswire
·
June 2, 2025
PALO ALTO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will …
Amerigo Announces Board Appointment
GlobeNewswire
·
June 2, 2025
VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Amerigo Resources Ltd. (TSX: ARG; ARREF:OTC) (“Amerigo” or the “Company”) is pleased to announce the appointment of Ignacio Cruz to the Company’s board of directors. Ignacio Cruz is a Civil …
Prelude Therapeutics to Participate in Upcoming Healthcare Conferences
GlobeNewswire
·
June 2, 2025
WILMINGTON, Del., June 02, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in two upcoming healthcare conferences in June. …
Emerita Provides Comments on Announcement Approving Development of Aznalcollar Project, Spain
GlobeNewswire
·
June 2, 2025
TORONTO, June 02, 2025 (GLOBE NEWSWIRE) -- Emerita Resources Corp. (TSX-V: EMO; OTCQB: EMOTF; FSE: LLJA) (the “Company” or “Emerita”) provides comments with respect to the announcement made on May 30, 2025 by the Minister of Energy and Mines of Andalucia, …
Dynacor Group Declares June 2025 Dividend
GlobeNewswire
·
June 2, 2025
MONTRÉAL, June 02, 2025 (GLOBE NEWSWIRE) -- Dynacor Group Inc. (TSX: DNG) ("Dynacor" or the "Corporation") announced its monthly dividend payment for June 2025 in the amount of C$0.01333 per common share which will be payable on June 18, 2025, to …
Groupe Dynacor déclare son dividende pour juin 2025
GlobeNewswire
·
June 2, 2025
MONTRÉAL, 02 juin 2025 (GLOBE NEWSWIRE) -- Groupe Dynacor Inc. (TSX : DNG) (« Dynacor » ou la « Société ») a le plaisir d’annoncer la déclaration de son dividende mensuel pour le mois de juin 2025 au montant de 0,01333$CA par action qui sera payé le 18 …
BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology
GlobeNewswire
·
June 2, 2025
RESEARCH TRIANGLE PARK, N.C., June 02, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that new data on oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) will be …
Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025
GlobeNewswire
·
June 2, 2025
Updated interim data remain consistent, showing 10.3-month median PFS overall and 11.0-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Data continue to support planned initiation of pivotal study in mid-2025 Next- …
Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD
GlobeNewswire
·
June 2, 2025
LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European Union (EU) and United Kingdom (UK) 2.8 million injections of repackaged off-label bevacizumab in Europe each year1 ISELIN, N.J., …